A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene. - Tsurutani,J.; Mitsudomi,T.; Mori,S. (ECCO/ESMO, 2009)